With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Educational research only - not investment advice, an offer, or a trade instruction. Confirm current data and do your own due diligence before acting.
MCK trades against a final fair-value range of $737.34-$1,307.92, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.
A stress scenario combining severe legislative pressure on drug prices with a sustained high-interest-rate environment would squeeze margins. If operating margins dip below 1.0% and the WACCWACCWeighted average cost of capital. The blended after-tax discount rate applied to free cash flows in a DCF, reflecting both equity and debt financing costs. normalizes to a higher tier, intrinsic valueIntrinsic valueThe discounted present value of all cash a business will produce over its remaining life. The theoretical anchor for fair value, computed in practice as a range across explicit assumptions. regressions toward the $737 downside boundary.
The loss of a massive retail pharmacy network customer significantly impairs revenue volume and devastates operating leverage.
Aggressive legislative action on drug pricing and PBM models compresses already razor-thin operating margins below 1.0%.
Unexpected expansion of opioid-related liabilities or new mass torts drain free cash flow, threatening the share buyback program.
| Line item | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | Trend |
|---|---|---|---|---|---|
| Revenue | $263.97B | $276.71B+4.8% | $308.95B+11.7% | $359.05B+16.2% | +10.8% |
| Gross profit | $13.13B | $12.36B | $12.83B | $13.32B | +0.5% |
| Operating income | $2.59B | $4.58B | $4.17B | $4.82B | +22.9% |
| Net income | $1.11B | $3.56B+220.7% | $3.00B-15.7% | $3.30B+10.0% | +43.5% |
| EPS (diluted) | $7.23 | $25.03 | $22.39 | $25.72 | +52.7% |
| EBITDA | $2.87B | $5.49B | $4.68B | $5.26B | +22.4% |
| R&D | — | — | — | — | — |
| SG&A | $10.54B | $7.78B | $8.66B | $8.51B | -6.9% |
Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
| Deterioration versus the report thesis |
| Slowing revenue growth in the higher-margin specialty oncology segment. | Monitor | Deterioration versus the report thesis |
| Deteriorating free cash flow conversion ratios. | Monitor | Deterioration versus the report thesis |
